TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36054481

Group type: EXPERIMENTAL
Intervention: Remote Delivery with Enhanced Stop Light Diet (RD/eSLD)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Remote Delivery with Conventional Diet (RD/CD)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Face-to-Face with Conventional Diet (FTF/CD)
Number of subjects: 92
Study: 34227958

Group type: EXPERIMENTAL
Intervention: Hypertensive group
Number of subjects: 430

Group type: COMPARATOR
Intervention: Non-hypertensive group
Number of subjects: 430
Study: 32271618

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) with concomitant valproate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) with concomitant clobazam
Number of subjects: 0
Study: 34717013

Group type: EXPERIMENTAL
Intervention: Barefoot retraining group (BAR)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Cadence retraining group (CAD)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 103
Study: 33284677

Group type: EXPERIMENTAL
Intervention: 1000 IU/d of vitamin D3
Number of subjects: 688

Group type: COMPARATOR
Intervention: 200 IU/d of vitamin D3 (control)
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: 2000 IU/d of vitamin D3
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: 4000 IU/d of vitamin D3
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: 1000 IU/d or higher doses of vitamin D3
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Experience-with-best-dose group (1000 IU/d)
Number of subjects: 688
Study: 32135126

Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg followed by misoprostol 200 mcg buccally
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo followed by misoprostol 200 mcg buccally
Number of subjects: 176
Study: 35763247

Group type: COMPARATOR
Intervention: Upacicalcet (0.025 to 0.8 mg single-dose)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Upacicalcet (0.05 to 0.2 mg multiple-dose)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 33413428

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 34378365

Group type: EXPERIMENTAL
Intervention: Olaparib plus bevacizumab
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo plus bevacizumab
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Olaparib plus bevacizumab (in homologous recombination deficiency positive tumors)
Number of subjects: 24
Study: 35333783

Group type: EXPERIMENTAL
Intervention: Targeted albumin infusions
Number of subjects: 143

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 143
Study: 32307430

Group type: EXPERIMENTAL
Intervention: Cytoflavin (intravenously, drip 20.0 ml in 250.0 ml 5% glucose for 14 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard treatment (Control group)
Number of subjects: 100
Study: 36297076

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory meal consumed two hours post-exercise
Number of subjects: 56

Group type: COMPARATOR
Intervention: Pro-inflammatory meal consumed two hours post-exercise
Number of subjects: 56
Study: 34015532

Group type: EXPERIMENTAL
Intervention: Genotypic resistance score (<0.5) for predicting phenotypic susceptibility
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Genotypic resistance score (≥1) for predicting resistance
Number of subjects: 204
Study: 35258771

Group type: EXPERIMENTAL
Intervention: Cognitive training intervention
Number of subjects: 58
Study: 32991818

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 66
Study: 36226798

Group type: EXPERIMENTAL
Intervention: Medication reminder app
Number of subjects: 275

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 275
Study: 33819329

Group type: EXPERIMENTAL
Intervention: Xenogeneic collagen matrix (n = 48)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Allogeneic acellular dermal matrix (n = 68)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Comparison between xenogeneic and allogeneic groups
Number of subjects: 19
Study: 35730363

Group type: EXPERIMENTAL
Intervention: Panel management intervention using PrEP Coordinators and a web-based panel management tool
Number of subjects: 10
Study: 34346168

Group type: EXPERIMENTAL
Intervention: 70 mg astegolimab every 4 weeks
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: 210 mg astegolimab every 4 weeks
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: 490 mg astegolimab every 4 weeks
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study: 36126073

Group type: EXPERIMENTAL
Intervention: Arca Aerosolized Hydrogen Peroxide Decontamination System with 3% H2O2 for 45 minutes
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control: 3% H2O2 for 120 minutes
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control: 12% H2O2 for 120 minutes
Number of subjects: 8

Group type: COMPARATOR
Intervention: Positive control: Not exposed to H2O2
Number of subjects: 8
Study: 33438713

Group type: EXPERIMENTAL
Intervention: Instrumental variable methods
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Mediation-based methods
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Coexpression-based methods
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Instrumental variable and mediation-based methods
Number of subjects: 1012
Study: 33736675

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate (0.82 mg/m2/week in group A to 0.65 mg/m2/week in group D)
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate
Number of subjects: 1062
Study: 32652581

Group type: EXPERIMENTAL
Intervention: Mentor perceptions of program practices (setting expectations, prematch mentor training, matching based on mentor preferences)
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Mentor commitment
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Program practices (setting clear expectations, amount of prematch training, matching by preferences)
Number of subjects: 537
Study: 34694189

Group type: EXPERIMENTAL
Intervention: Exoskeleton-based physiotherapy
Number of subjects: 14
Study: 33444970

Group type: EXPERIMENTAL
Intervention: Almond consumption (2 servings, 56 g/day)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Biscuit snack (isocaloric, high carbohydrate)
Number of subjects: 69
Study: 33422409

Group type: EXPERIMENTAL
Intervention: SAFMEDS intervention with usual teaching
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual teaching only (Control)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SAFMEDS intervention with usual teaching (Fluency Achieved)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SAFMEDS intervention with usual teaching (Fluency Not Achieved)
Number of subjects: 42
Study: 36495483

Group type: EXPERIMENTAL
Intervention: Oral ulipristal acetate regimens
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Higher-body mass index (BMI) women
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Overall population analysis
Number of subjects: 135
Study: 33568086

Group type: EXPERIMENTAL
Intervention: Cochlear implants (CI) in children aged 4-6 years
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cochlear implants (CI) in children aged 7-9 years
Number of subjects: 38

Group type: COMPARATOR
Intervention: Normal hearing peers (control group)
Number of subjects: 38
Study: 35869569

Group type: EXPERIMENTAL
Intervention: Montessori-Based Nutrition Program
Number of subjects: 51
Study: 33573687

Group type: EXPERIMENTAL
Intervention: Nurse-led lifestyle choice and coaching intervention
Number of subjects: 388

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 388
Study: 34637450

Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA) intervention, median 6 sessions out of 8, delivered remotely.
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA) intervention.
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual primary care (control group).
Number of subjects: 96
Study: 32451005

Group type: EXPERIMENTAL
Intervention: Gordon's functional health pattern model nursing care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard nursing care
Number of subjects: 120
Study: 34894266

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg BID
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 32541143

Group type: EXPERIMENTAL
Intervention: Temsirolimus (TEM) 25 mg i.v. once a week
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sunitinib (SUN) 50 mg p.o. daily for 4 weeks on and 2 weeks off
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sunitinib (SUN)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Temsirolimus (TEM)
Number of subjects: 22
Study: 36375173

Group type: EXPERIMENTAL
Intervention: 30 mg duloxetine
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 60 mg duloxetine
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 34082620

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 11795

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 11795

Group type: EXPERIMENTAL
Intervention: Anemia treatment (iron, erythropoiesis-stimulating agents, and/or red blood cell transfusion)
Number of subjects: 11795

Group type: COMPARATOR
Intervention: No anemia treatment
Number of subjects: 11795
Study: 33103322

Group type: COMPARATOR
Intervention: Novel treatments
Number of subjects: 134
Study: 33440077

Group type: EXPERIMENTAL
Intervention: Letermovir (oral and intravenous administration)
Number of subjects: 0
Study: 32499026

Group type: EXPERIMENTAL
Intervention: Bioresorbable-polymer sirolimus-eluting stents (BP SES)
Number of subjects: 1334

Group type: COMPARATOR
Intervention: Durable-polymer everolimus-eluting stents (DP EES)
Number of subjects: 1334
Study: 34391038

Group type: EXPERIMENTAL
Intervention: Healthy achievement condition (emphasis on social support and connection)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard motivation condition
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Healthy achievement condition
Number of subjects: 39
Study: 33866430

Group type: EXPERIMENTAL
Intervention: MYL‐1402O
Number of subjects: 111

Group type: COMPARATOR
Intervention: EU-reference bevacizumab
Number of subjects: 111

Group type: COMPARATOR
Intervention: US-reference bevacizumab
Number of subjects: 111

Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 111
Study: 33741803

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0
Study: 32609313

Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg once daily for 12 weeks
Number of subjects: 3623

Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg once daily for 52 weeks
Number of subjects: 3623

Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg once daily for 24 weeks
Number of subjects: 3623

Group type: EXPERIMENTAL
Intervention: Bempedoic acid
Number of subjects: 3623
Study: 35362109

Group type: EXPERIMENTAL
Intervention: QFR-based treatment recommendations
Number of subjects: 260

Group type: COMPARATOR
Intervention: FFR-based treatment recommendations
Number of subjects: 260
Study: 32961094

Group type: EXPERIMENTAL
Intervention: Palivizumab prophylaxis
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control (pre-2013)
Number of subjects: 147
Study: 33296982

Group type: EXPERIMENTAL
Intervention: Salbutamol 2 mg twice a day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 33853157

Group type: EXPERIMENTAL
Intervention: Knee distraction
Number of subjects: 0

Group type: COMPARATOR
Intervention: High tibial osteotomy
Number of subjects: 0
Study: 35182906

Group type: EXPERIMENTAL
Intervention: Auditory neuroscience-informed cognitive training
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Visual neuroscience-informed cognitive training
Number of subjects: 79
Study: 34302758

Group type: EXPERIMENTAL
Intervention: Itepekimab 300 mg administered as two subcutaneous injections every 2 weeks for 24-52 weeks
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Itepekimab in former smokers
Number of subjects: 343

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study: 32106835

Group type: EXPERIMENTAL
Intervention: Intervention engagement and adherence
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 729
Study: 34654026

Group type: EXPERIMENTAL
Intervention: 10 mg enalapril and 0.8 mg folic acid
Number of subjects: 20688

Group type: COMPARATOR
Intervention: 10 mg enalapril alone
Number of subjects: 20688
Study: 34231962

Group type: EXPERIMENTAL
Intervention: Psychological nursing interventions
Number of subjects: 106

Group type: COMPARATOR
Intervention: Conventional nursing care (Control)
Number of subjects: 106
Study: 35771495

Group type: EXPERIMENTAL
Intervention: MBT-DH
Number of subjects: 114

Group type: COMPARATOR
Intervention: MBT-IOP
Number of subjects: 114
Study: 32654836

Group type: EXPERIMENTAL
Intervention: Social media messages (visual based, quiz, text only)
Number of subjects: 928

Group type: COMPARATOR
Intervention: No-message control
Number of subjects: 928
Study: 32936085

Group type: EXPERIMENTAL
Intervention: Individually tailored transdiagnostic guided internet intervention for anxiety disorders (7-session intervention)
Number of subjects: 49
Study: 35430997

Group type: EXPERIMENTAL
Intervention: Ibuprofen/Caffeine combination (400/100 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ibuprofen alone
Number of subjects: 26
Study: 33504513

Group type: EXPERIMENTAL
Intervention: Double-dose clopidogrel (600 mg, day 1; 150 mg, days 2-7; then 75 mg/day)
Number of subjects: 1599

Group type: COMPARATOR
Intervention: Standard-dose clopidogrel (300 mg, day 1; then 75 mg/day)
Number of subjects: 1599

Group type: COMPARATOR
Intervention: Patients with obstructive CAD (control group)
Number of subjects: 1599

Group type: EXPERIMENTAL
Intervention: MINOCA patients
Number of subjects: 1599
Study: 34302129

Group type: EXPERIMENTAL
Intervention: 1.5 g l-arginine and 1.2 g aged garlic extract (AGE) daily for 6 weeks
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1
Study: 33166759

Group type: EXPERIMENTAL
Intervention: Florfenicol resistance gene detection (floR)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Minimum inhibitory concentration (MIC) determination for florfenicol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bacterial identification
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sequence analysis of floR
Number of subjects: 30
Study: 35711483

Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 60
Study: 33154429

Group type: EXPERIMENTAL
Intervention: EHR alert activation
Number of subjects: 8299

Group type: COMPARATOR
Intervention: Control (no alert)
Number of subjects: 8299
Study: 36364748

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (150,000 IU in vegetable oil 24 h before the run)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study: 33087061

Group type: EXPERIMENTAL
Intervention: Advanced Care Planning (ACP) program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual follow-up and care (Control)
Number of subjects: 0
Study: 34281958

Group type: EXPERIMENTAL
Intervention: High oxalate quartile (≥59.7 µM)
Number of subjects: 1255
Study: 33496884

Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with Zn-Met 60 mg/kg (T3)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with Zn-Met 40 mg/kg (T2)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with Zn-Met 20 mg/kg (T1)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Basal diet (control, 40 mg/kg)
Number of subjects: 480
Study: 32356023

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg kg‐1)
Number of subjects: 18
Study: 32323557

Group type: EXPERIMENTAL
Intervention: Vitamin D treatment (150,000 IU daily for 3 days before surgery)
Number of subjects: 70
Study: 33632715

Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 0
Study: 32155773

Group type: EXPERIMENTAL
Intervention: Enriched Sport Activity Program (ESA) with additional warm-up protocol for 14 weeks
Number of subjects: 672

Group type: COMPARATOR
Intervention: Ordinary exercise activity (Control)
Number of subjects: 672
Study: 34590235

Group type: EXPERIMENTAL
Intervention: Office-based extended-release naltrexone
Number of subjects: 116

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 116
Study: 33254239

Group type: EXPERIMENTAL
Intervention: Therapist supported self-management programme plus a verum thumb splint (SSM+S)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Therapist supported self-management programme plus a placebo thumb splint (SSM+PS)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Therapist supported self-management programme (SSM)
Number of subjects: 349
Study: 32173650

Group type: EXPERIMENTAL
Intervention: Cy/GVAX plus degarelix
Number of subjects: 0

Group type: COMPARATOR
Intervention: Degarelix alone
Number of subjects: 0
Study: 36453001

Group type: EXPERIMENTAL
Intervention: Narrative therapy group sessions (8 weekly 2-hour sessions)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Current model of psychoeducational group (control)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Narrative therapy
Number of subjects: 200
Study: 32777055

Group type: EXPERIMENTAL
Intervention: Early adenotonsillectomy (eAT)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Watchful waiting with supportive care (WWSC)
Number of subjects: 365
Study: 35948454

Group type: EXPERIMENTAL
Intervention: Strength training plus proprioceptive neuromuscular facilitation (PNF) therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Strength training
Number of subjects: 42
Study: 35287479

Group type: EXPERIMENTAL
Intervention: Fall Arrest Strategy Training (FAST)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard fall prevention exercises
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both FAST and Standard
Number of subjects: 40
Study: 35191898

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: DEXA (Dual-energy x-ray absorptiometry)
Number of subjects: 33
Study: 34683948

Group type: EXPERIMENTAL
Intervention: GF:IF = 0.5 with cumulative dose of 1.5 mg salbutamol
Number of subjects: 75

Group type: COMPARATOR
Intervention: GF:IF = 1.0 with cumulative dose of 1.5 mg salbutamol
Number of subjects: 75

Group type: COMPARATOR
Intervention: GF = 50 L/min with cumulative dose of 1.5 mg salbutamol
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: GF:IF = 0.5 with cumulative dose of 3.5 mg salbutamol
Number of subjects: 75

Group type: COMPARATOR
Intervention: GF:IF = 1.0 with cumulative dose of 3.5 mg salbutamol
Number of subjects: 75

Group type: COMPARATOR
Intervention: GF = 50 L/min with cumulative dose of 3.5 mg salbutamol
Number of subjects: 75
Study: 35794674

Group type: EXPERIMENTAL
Intervention: Intravenous morphine at a rate of 1 mg/h for the first 6 hours postoperatively, with adjustments based on NRS pain evaluation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen 1 g every 6 hours and ketorolac 30 mg every 8 hours for the first 3 postoperative days
Number of subjects: 0
Study: 33386290

Group type: EXPERIMENTAL
Intervention: Optimal local treatment for nodal oligorecurrent prostate cancer
Number of subjects: 0
Study: 37405698

Group type: EXPERIMENTAL
Intervention: SKILLZ intervention (sport-based, near-peer-led SRH curriculum)
Number of subjects: 2791

Group type: EXPERIMENTAL
Intervention: SKILLZ intervention (high attendance participants)
Number of subjects: 2791

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2791
Study: 32938484

Group type: EXPERIMENTAL
Intervention: Echocardiography (ASE formula)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Echocardiography (Th formula)
Number of subjects: 95

Group type: COMPARATOR
Intervention: CMR (reference method)
Number of subjects: 95
Study: 34978530

Group type: EXPERIMENTAL
Intervention: ICU-specific virtual reality (ICU-VR)
Number of subjects: 89
Study: 34058883

Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 151
Study: 35842821

Group type: EXPERIMENTAL
Intervention: Absorbable macroporous polysaccharide composites (AMPC)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Compound microporous polysaccharide hemostatic powder (CMPHP)
Number of subjects: 252
Study: 32229495

Group type: EXPERIMENTAL
Intervention: Contezolid (MRX-I) therapeutic dose (800 mg)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Contezolid (MRX-I) supratherapeutic dose (1,600 mg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Contezolid (MRX-I)
Number of subjects: 52
Study: 34797500

Group type: EXPERIMENTAL
Intervention: Quick Wee Method (supra-pubic stimulation with cold saline)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care (clean catch with no bladder stimulation)
Number of subjects: 140
Study: 33845127

Group type: EXPERIMENTAL
Intervention: e‐consult® application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Consultation without e‐consult®
Number of subjects: 0
Study: 35807913

Group type: EXPERIMENTAL
Intervention: Eight‐week interdisciplinary weight loss and lifestyle intervention combined with usual‐care
Number of subjects: 89

Group type: COMPARATOR
Intervention: Usual-care
Number of subjects: 89
Study: 32507624

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ) supplementation (140 mL nitrate-rich BJ concentrate)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 32763006

Group type: EXPERIMENTAL
Intervention: Ceramic femoral head (BIOLOX delta)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Metal femoral head (CoCr)
Number of subjects: 50
Study: 36044708

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO: 1 g/kg/h)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (CON: nutrient free)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Let7i‐5p
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: miR‐195‐5p
Number of subjects: 7
Study: 33705205

Group type: EXPERIMENTAL
Intervention: Adavosertib monotherapy (300 mg orally once daily on days 1-5 and 8-12 of a 21-day cycle)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Adavosertib monotherapy
Number of subjects: 34